1. Home
  2. HLXC vs IMRX Comparison

HLXC vs IMRX Comparison

Compare HLXC & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HLXC

Helix Acquisition Corp. III Class A Ordinary Shares

N/A

Current Price

$10.27

Market Cap

233.2M

Sector

N/A

ML Signal

N/A

Logo Immuneering Corporation

IMRX

Immuneering Corporation

N/A

Current Price

$3.62

Market Cap

232.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HLXC
IMRX
Founded
2025
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.2M
232.3M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
HLXC
IMRX
Price
$10.27
$3.62
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $17.00
AVG Volume (30 Days)
56.5K
★ 727.6K
Earning Date
01-01-0001
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 37.75
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$10.11
$3.35
52 Week High
$11.23
$8.48

Technical Indicators

Market Signals
Indicator
HLXC
IMRX
Relative Strength Index (RSI) 38.64 45.19
Support Level $10.14 $3.37
Resistance Level $10.30 $4.16
Average True Range (ATR) 0.02 0.26
MACD 0.01 0.02
Stochastic Oscillator 66.67 33.54

Price Performance

Historical Comparison
HLXC
IMRX

About HLXC Helix Acquisition Corp. III Class A Ordinary Shares

Helix Acquisition Corp III is a blank check company.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: